Clinical Trials › NCT05877963
RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Sponsored by TG Therapeutics, Inc.
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 800
Target enrollment
25
U.S. states
Jun 2023
Start date
Dec 2027
Expected completion
Interventions / Treatments
UblituximabPlacebo
Conditions studied
Relapsing Multiple Sclerosis
Where this trial is running (35 sites)
Massachusetts4 sites
Boston · Foxborough · North Worcester · +1 more
Washington3 sites
Kirkland · Seattle · Spokane
Alabama2 sites
Birmingham · Cullman
Minnesota2 sites
Golden Valley · Plymouth
New York2 sites
New York · New York
North Carolina2 sites
Charlotte · Raleigh
Ohio2 sites
Cleveland · Dayton
California1 site
Orange
Colorado1 site
Fort Collins
District of Columbia1 site
Washington D.C.
Florida1 site
Tampa
Illinois1 site
Chicago
Indiana1 site
Indianapolis
Iowa1 site
Iowa City
Kansas1 site
Overland Park
Maryland1 site
Lutherville
Michigan1 site
Farmington
Missouri1 site
St Louis
Oklahoma1 site
Oklahoma City
South Carolina1 site
Greenville
Tennessee1 site
Knoxville
Texas1 site
Houston
Utah1 site
Salt Lake City
Virginia1 site
Vienna
Wisconsin1 site
Milwaukee
MS centers in Massachusetts
Compare treatment centers near a trial site — patient experience, providers, and care ratings.
View Massachusetts centersMore Phase 3 trials
Browse all Phase 3 MS trialsCheck out the MS Buddy App
Track symptoms, monitor wellness, and stay on top of your MS care. It's free, no ads. How? It's made and supported by MS patients who get their ideas from other MS patients.
